Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

Carlos H. Barcenas, MD
Published: Tuesday, Feb 14, 2017



Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

In an effort to keep patients on neratinib for an entire year, Barcenas is currently evaluating agents to see which will successfully treat the common side effect of diarrhea.

Colestipol, a bile acid sequestrant, has shown promise in managing diarrhea in patients with metastatic HER2-positive breast cancer who are on neratinib.
 
SELECTED
LANGUAGE


Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

In an effort to keep patients on neratinib for an entire year, Barcenas is currently evaluating agents to see which will successfully treat the common side effect of diarrhea.

Colestipol, a bile acid sequestrant, has shown promise in managing diarrhea in patients with metastatic HER2-positive breast cancer who are on neratinib.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x